octreotide
Sandostatin is a synthetic derivative of somatostatin, a substance that occurs naturally in the human body and inhibits the action of certain hormones, such as growth hormone. Sandostatin acts more strongly than somatostatin and its action lasts longer.
ineffective;
Before starting treatment with Sandostatin, discuss with your doctor:
If you are being treated with Sandostatin for a long time, your doctor may order periodic checks of your thyroid function.
Your doctor will check your liver function.
Your doctor may order checks of your pancreatic enzyme levels.
There is limited experience with the use of Sandostatin in children.
Tell your doctor or pharmacist about all the medicines you are taking, have recently taken, or might take.
During treatment with Sandostatin, you can usually continue taking other medicines. However, it has been reported that Sandostatin affects the action of certain medicines, such as cimetidine, cyclosporine, bromocriptine, quinidine, and terfenadine.
If you are taking a medicine to control your blood pressure (such as a beta-blocker or calcium channel blocker), or a medicine to maintain fluid and electrolyte balance, your doctor may adjust the dose.
In patients with diabetes, it may be necessary to adjust the insulin dose.If you are to receive lutetium (Lu) oxodotreotide therapy, a radiopharmaceutical treatment, your doctor may stop and/or adjust Sandostatin treatment.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, ask your doctor for advice before taking this medicine.
Sandostatin should only be used during pregnancy if clearly necessary.
Women of childbearing age should use effective contraception during treatment.
Do not breastfeed while taking Sandostatin. It is not known whether Sandostatin passes into breast milk.
Sandostatin has no or negligible influence on the ability to drive and use machines. However, certain side effects that may occur during treatment with Sandostatin, such as headache and fatigue, may reduce the patient's ability to drive and use machines safely.
This medicine contains less than 1 mmol (23 mg) of sodium per ampoule, which means it is essentially 'sodium-free'.
This medicine should always be used as directed by your doctor or pharmacist. If you are unsure, ask your doctor or pharmacist.
Depending on the disease being treated, Sandostatin may be given:
In the case of liver cirrhosis (chronic liver disease), your doctor may adjust the maintenance dose.
Your doctor or nurse will explain to you how to inject Sandostatin under the skin, while intravenous infusion must always be performed by medical personnel.
The recommended site for subcutaneous injections is the upper part of the arms, thighs, or abdomen.
A new site should be chosen for each injection to avoid tissue irritation. Your doctor or nurse will provide detailed instructions on how to administer the medicine to patients who will be self-administering subcutaneous injections.
If the medicine is stored in the refrigerator, it is recommended to bring the ampoules to room temperature before administration. This will reduce the risk of pain at the injection site. You can warm the ampoule in your hands, but do not heat it.
Some patients experience pain at the subcutaneous injection site. This pain is usually short-lived. If pain occurs, it can be alleviated by gently rubbing the injection site for a few seconds after administering the medicine.
Before administering the contents of the Sandostatin ampoule, check that the solution does not contain particles or has not changed color. Do not administer the medicine if changes in the appearance of the solution are observed.
Symptoms of overdose include: irregular heartbeat, low blood pressure, cardiac arrest, brain hypoxia, severe upper abdominal pain, yellowing of the skin and eyes, nausea, loss of appetite, diarrhea, weakness, fatigue, lack of energy, weight loss, abdominal swelling, discomfort, high levels of lactic acid in the blood, and abnormal heart rhythm.
If you think you have taken too much Sandostatin and are experiencing these symptoms, tell your doctor immediately.
Take one dose as soon as you remember, and then continue with the treatment as before. Missing a dose is not harmful, but it may cause a temporary recurrence of disease symptoms until the planned treatment schedule is resumed.
Do not inject a double dose to make up for a missed dose.
After stopping treatment with Sandostatin, disease symptoms may recur. Therefore, do not stop taking Sandostatin without consulting your doctor.
If you have any further questions about the use of this medicine, ask your doctor, nurse, or pharmacist.
Like all medicines, Sandostatin can cause side effects, although not everybody gets them.
Very common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
If you notice any of the above symptoms, tell your doctor immediately.
If you notice any of the following side effects, tell your doctor, pharmacist, or nurse. These effects are usually mild and tend to disappear as treatment progresses.
Very common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
If you experience any side effects, tell your doctor, nurse, or pharmacist.
Some patients experience pain at the subcutaneous injection site. This pain is usually short-lived. If pain occurs, it can be alleviated by gently rubbing the injection site for a few seconds after administering the medicine.
The occurrence of gastrointestinal side effects may be reduced by avoiding meals shortly before or after subcutaneous administration of Sandostatin, i.e., injecting between meals or before going to bed.
If you experience any side effects, including those not listed in this leaflet, tell your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Al. Jerozolimskie 181C
02-222 Warsaw
tel.: 22 49-21-301
fax: 22 49-21-309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep the medicine out of the sight and reach of children.
Store in the original packaging to protect from light.
Store in the refrigerator (2 °C – 8 °C). Do not freeze.
Ampoules can be stored at a temperature below 30 °C for no more than 2 weeks.
Ampoules should be used immediately after opening.
The diluted solution should be used immediately after preparation.
Do not use this medicine after the expiry date stated on the label and packaging after "EXP" and "Expiry Date (EXP)". The expiry date refers to the last day of the month stated.
Do not use this medicine if you notice particles or a change in color.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Ampoules of colorless glass with two colored coding rings, containing a clear, colorless solution.
Sandostatin 50 micrograms/1 ml: one blue and one yellow
Sandostatin 100 micrograms/1 ml: one blue and one green
The medicine is available in packs containing 5 ampoules of 1 ml each.
Novartis Poland Sp. z o.o.
Marynarska 15
02-674 Warsaw
Tel. + 48 22 375 48 88
Novartis Poland Sp. z o.o.
Marynarska 15
02-674 Warsaw
Novartis Pharma GmbH
Jakov-Lind-Straße 5, Top 3.05
1020 Wien
Austria
Novartis Pharma NV
Medialaan 40 Bus 1
Vilvoorde, B-1800
Belgium
Novartis Healthcare A/S
Edvard Thomsens Vej 14
Copenhagen S, 2300
Denmark
Novartis Finland Oy
Metsäneidonkuja 10
Espoo, FI-02130
Finland
Novartis Pharma SAS
8-10 rue Henri Sainte-Claire Deville
92500 Rueil Malmaison
France
Novartis Pharma GmbH
Roonstrasse 25
90429 Nürnberg
Germany
Novartis Pharma GmbH
Sophie-Germain-Strasse 10
90443 Nürnberg
Germany
Novartis (HELLAS) SA
12th km National Road Athinon-Lamias
Metamorfosi Attiki, 14451
Greece
Novartis Hungária Kft.
Vasút u.13
Budaörs, 2040
Hungary
Novartis Farma S.p.A.
Via Provinciale Schito 131
80058 Torre Annunziata (NA)
Italy
Novartis Farma - Produtos Farmacêuticos, S.A.
Avenida Professor Doutor Cavaco Silva, n.10E,Taguspark
Porto Salvo, 2740-255
Portugal
Novartis Farmacéutica S.A.
Gran Via de les Corts Catalanes, 764
08013 Barcelona
Spain
Novartis Sverige AB
Torshamnsgatan 48
164 40 Kista
Sweden
Novartis Pharma B.V.
Haaksbergweg 16
1101 BX Amsterdam
Netherlands
Sandostatin
Austria, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Germany, Greece, Hungary, Iceland, Ireland, Latvia, Lithuania, Malta, Norway, Poland, Romania, Slovakia, Slovenia, Spain, Sweden
Sandostatine
Belgium, France, Luxembourg, Netherlands
Sandostatina
Italy, Portugal
Information intended for healthcare professionals only:
Before using the Sandostatin ampoule, visually inspect the solution for particles or color change. Do not administer if changes in the appearance of the solution are observed.
Dilute the solution before administering the medicine by intravenous infusion.
Sandostatin (octreotide acetate) is physically and chemically stable for 24 hours in physiological saline or 5% glucose solution in water. Since Sandostatin may affect glucose homeostasis, physiological saline is recommended instead of glucose. Diluted solutions are physically and chemically stable for at least 24 hours at a temperature below 25 °C. From a microbiological point of view, diluted solutions should be used immediately after preparation. If the solution is not used immediately, the user is responsible for the storage time and conditions before use.
The contents of one ampoule (500 micrograms) are usually dissolved in 60 ml of 0.9% sodium chloride solution, and the resulting solution is administered using an infusion pump. This procedure should be repeated as often as necessary to achieve the prescribed treatment time.
The dosage of Sandostatin depends on the disease being treated.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.